With 43.2% CAGR, Global CAR-T Cell Therapy Market Size Envisaged to reach USD 118,680.68 Million By 2032: Polaris Market Research

Home With 43.2% CAGR, Global CAR-T Cell Therapy Market Size Envisaged to reach USD 118,680.68 Million By 2032: Polaris Market Research
Written by Doug Hampton

NEW YORK, May 29, 2023 /PRNewswire/ — A latest research report [115+] pages with 360-Degree visibility, titled “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report, By Target Antigen (CD19/CD22, BCMA, and Others); By Indication; By Region; Segment Forecast, 2023 – 2032” published by Polaris Market Research in its research repository.

“According to research report, the global car-t cell therapy market size/share was valued at USD 3,010.24 Million in 2022 and is expected to touch USD 118,680.68 Million By 2032, growing at a CAGR of 43.2% during the forecast period.”

What is CAR-T Cell Therapy? How Big is CAR-T Cell Therapy Market Size?

CAR-T cell therapy, known as Chimeric antigen receptor, is a ground-breaking new component in cancer treatment. It treats specific cancers by turning your T-cells into more effective cancer-fighting machines. This treatment has shown considerable promise in curing some types of blood cancers by using your own immune cells to combat cancer, resulting in increased demand for the CAR-T cell therapy market.

With CAR-T cell treatment, immune cells named T cells are taken out of the blood and given a new gene that makes them capable of identifying cancer. The T cells are injected back into the circulation once the gene has been added, where they multiply and start a range of immunological reactions meant to kill the cancer cells. It treats particular types of cancer like pediatric leukemia, lymphoma, and adult leukemia.

Request Sample Copy of CAR-T Cell Therapy Market Research Report @ https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/request-for-sample 

(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, Table of Contents, Graphical introduction of regional analysis, Top players in the market with their revenue analysis and our research methodology.)

Our Sample Report May Includes:

  • 2032 Updated Report Introduction, Overview, and In-depth industry analysis.
  • 115+ Pages Research Report (Inclusion of Updated Research).
  • Provide Chapter-wise guidance on Request.
  • 2023 Updated Regional Analysis with Graphical Representation of Size, Share & Trends.
  • Includes Updated List of table & figures.
  • Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis.

Some of the Top Market Players Are:

  • Amgen Inc. (US)
  • Bellicum Pharmaceuticals Inc. (US)
  • Bluebird Bio (US)
  • Caribou Biosciences Inc. (US)
  • Celgene Corporation
  • Cellectis
  • Celyad
  • Gilead Sciences Inc.
  • Intellia Therapeutics
  • Johnson & Johnson
  • Merck KGaA
  • Nanjing Legend Biotechnology Co. Ltd.
  • Noile-Immune Biotech
  • Novartis International AG
  • Pfizer Inc.
  • Sangamo Therapeutics Inc.
  • Servier Laboratories

For Additional Information on Key Players, Request to Download Sample Pages Here: https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/request-for-sample 

Key Growth Driving Factors

  • Increased Prevalence of Cancer: During the projection period, the number of patient assistance programs, government initiatives to raise cancer awareness, and growing cancer prevalence all contributed to the CAR-T cell therapy market growth.
  • Identification of CAR-T Therapy Potential: The potential of CAR-T cell therapy has been acknowledged by biotechnology companies, major pharmaceutical businesses, and academic associations, who have invested greatly in this field. These investments seek to increase manufacturing capacity, accelerate R&D, and increase access to CAR-T therapy for more patients.
  • Increased Investments: The market has made great progress due to increased investment, with various medicines getting regulatory authorization and going on sale. The additional funding is anticipated to accelerate CAR-T therapy development and commercialization, opening the door for more effective and individualized cancer treatments.

Request for a Discount on this Report Before Purchase @ https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/request-for-discount-pricing

Recent Trends Influencing the Market

  • Innovative Approach: Major companies have recently increased their CAR-T cell treatment business investments. A new cancer treatment method called CAR-T (Chimeric Antigen Receptor T-cell) therapy involves altering a patient’s immune cells to find and kill cancer cells.
  • Major Priority of Investments: The investments have focused on streamlining production methods, increasing clinical trials, and enhancing CAR-T therapy’s scalability and economic feasibility. Major corporations also invest in partnerships and collaborations with smaller biotech firms to exploit their expertise and advanced technology in CAR-T development.

Segmental Analysis

  • CD19/CD22 Holds the Greatest Market Share

CD19/CD22 dominates the Car-T cell therapy market share. Impressive clinical results have been seen with CD19-targeted CAR-T therapy when treating specific forms of lymphoma and leukemia. They have received regulatory approval and have proven effective in causing patient remission.

The market dynamics are evolving, and the development of BCMA-targeted CAR-T treatments for multiple myeloma has attracted much interest. Myeloma cells strongly express BCMA, which makes it a desirable target for CAR-T cell treatment. BCMA-targeted CAR-T treatments have demonstrated excellent response rates and long-lasting remissions in patients with relapsed or refractory multiple myeloma in early clinical trials, which have yielded encouraging findings.

  • Diffuse Large B-Cell Lymphoma (DLBCL) Holds the Largest Share

DLBCL is one of the most prevalent types of non-Hodgkin lymphoma and is characterized by rapidly growing tumors of B-cell origin. It is a significant indication in the CAR-T cell therapy market and holds a considerable market share.

The use of CAR-T cell therapy in treating DLBCL has delivered encouraging results. CAR-T therapy improves the immune system’s capacity to identify and destroy cancer cells by genetically altering a patient’s own T cells to express CARs that target particular proteins in cancer cells.

Inquire more about this report before purchase @ https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/inquire-before-buying 

(Inquire a report quote OR available discount offers to the sales team before purchase.)

CAR-T Cell Therapy Market: Report Scope

Report Attribute


Revenue forecast in 2032

USD 118,680.68 Million

Market size value in 2023

USD 4,674.30 Million

Expected CAGR Growth

43.2% from 2023 – 2032

Base Year


Forecast Year

2023 – 2032

Top Market Players

Amgen Inc. (US), Bellicum Pharmaceuticals, Inc. (US), Bluebird Bio (US), Caribou Biosciences, Inc. (US), Celgene Corporation, Cellectis, Celyad, Gilead Sciences, Inc., Intellia Therapeutics, Johnson & Johnson, Merck KGaA, Nanjing Legend Biotechnology Co., Ltd., Noile-Immune Biotech, Novartis International AG, Pfizer Inc., Sangamo Therapeutics, Inc., Servier Laboratories.

Segments Covered

By Target Antigen, By Indication, By Region

Customization Options

Customized purchase options are available to meet any research needs. Explore customized purchase options

Geographical Overview

  • North America: A growing number of cancer patients and the development of the biotech industry in North America are likely to make the region the leader in the worldwide CAR-T cell treatment industry. The number of cancer cases in North America is rising, driving demand for cancer treatments there.
  • European Countries: The CAR-T treatment market will expand quickly due to changing European market trends and the rising adoption of suitable technology. The Committee for Medicinal Products for Human Use (CHMP) gave Kymriah and Yescarta favorable reviews, making them the first medications funded by the EMA’s Priority Medicines (PRIME) program. As a result, an increase in CAR-T cell therapy market size is anticipated.

Browse the Detail Report “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report, By Target Antigen (CD19/CD22, BCMA, and Others); By Indication; By Region; Segment Forecast, 2023 – 2032″ with in-depth TOC: https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market       

For Additional Information OR Media Enquiry, Please Mail At: [email protected] 

Recent Developments

  • Seattle Genetics, Inc. and Merck teamed together in September 2020 for two strategic oncology trials to create cures for various malignancies. Individuals with melanoma with lymph node involvement following surgery will receive Merck’s KEYTRUDA as adjuvant therapy as part of the agreement.
  • Atara Biotherapeutics, Inc. and Bayer AG partnered in December 2020 to create mesothelin-targeted CAR T-cell treatments for solid tumors. By progressing ATA2271 for treating malignant pleural mesothelioma and non-small-cell lung cancer, this partnership established Atara as a top producer of allogeneic CAR-T cell therapy.

Key Questions Answered in The Report

  • What are the driving factors for the growth of the market?
  • Who are the CAR-T cell therapy market key players?
  • What is the estimated industry size of CAR-T cell therapy?
  • How big is the CAR-T cell therapy industry?
  • What will be the CAGR of the CAR-T cell therapy market?
  • Which is the largest regional market for CAR-T cell therapy?
  • What’s their company profile, product information, and contact information?
  • What is market chain analysis by upstream raw materials and downstream industry?
  • What are the challenges and opportunities?

Polaris Market Research has segmented the CAR-T Cell Therapy market report based on target antigen, indication, and region:

By Target Antigen Outlook

  • CD19/CD22
  • BCMA (B-Cell Maturation Antigen)
  • Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Ra2, LewisY)

By Indication Outlook

  • ALL
  • CLL
  • MM
  • FL
  • Mastozytosis
  • Myeloid Fibrosis
  • MLL
  • Thymic Cancer
  • Glioblastoma
  • AML
  • Others

By Region Outlook

  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

Browse More Research Reports:

About Polaris Market Research:

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR’s clientele spread across different enterprises. We at Polaris are obliged to serve PMR’s diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide PMR’s customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR’s customers.


Likhil G
30 Wall Street
8th Floor,
New York City, NY 10005,
United States
Phone: +1-929 297-9727
Email: [email protected]
Web: https://www.polarismarketresearch.com 
Follow Us: LinkedIn twitter
Blog: https://polarismarketresearch.medium.com

Logo: https://mma.prnewswire.com/media/1316207/Polaris_Market_Research_Logo.jp

SOURCE Polaris Market Research

Leave a Comment